Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

Overview of attention for article published in Cost Effectiveness and Resource Allocation, November 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 19 Mendeley

Summary Blogs Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 21 Aug 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.